Alternatives to antibiotics—a pipeline portfolio review

Lloyd G. Czaplewski(University of Kent), Richard Bax, Martha R. J. Clokie(University of Leicester), Mike Dawson(Hertfordshire Community NHS Trust), Heather Fairhead, Vincent A. Fischetti(Rockefeller University), Simon J. Foster(Absynth Biologics (United Kingdom)), Brendan Gilmore(Queen's University Belfast), Robert E. W. Hancock(University of British Columbia), David J. Harper(University of Bedfordshire), Ian R. Henderson(University of Birmingham), Kai Hilpert(St George's, University of London), Brian V. Jones(Queen Victoria Hospital NHS Foundation Trust), Aras Kadioglu(University of Liverpool), DAVID J. C. KNOWLES(Procarta Biosystems (United Kingdom)), Sigríður Ólafsdóttir(Icelandic Meteorological Office), David Payne(GlaxoSmithKline (United States)), Steve Projan, Sunil Shaunak(Imperial College London), Jared Silverman, Christopher M. Thomas(The Edgbaston Hospital), T J Trust(Pan-Provincial Vaccine Enterprise), Peter Warn(Evotec (United Kingdom)), John Rex(AstraZeneca (Brazil))
The Lancet Infectious Diseases
January 13, 2016
Cited by 841Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis